← Back to headlines
BioMarin to Acquire Hypophosphatasia Drug Through Alesta Buyout
BioMarin Pharmaceutical is set to gain a hypophosphatasia drug as part of its acquisition of Alesta.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Wizz Air Offers to Take Over TAROM's Domestic Routes, Sparking Controversy
24m ago
Guggenheim Investments Considers Buying Its Beleaguered Loan Amid Federal Probe
35m ago
Alpha Metallurgical Resources Directors Acquire Millions in Shares
35m ago
Football Clubs' Champions League Aspirations and Earnings
41m ago